FT819 in Subjects With B-cell Malignancies
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)
Current Status: Open
Phase: I (Cancer Control)
Principal Investigator: D'Angelo, Christopher
Eligibility: https://clinicaltrials.gov/study/NCT04629729?term=NCT04629729&rank=1
Summary
Primary: To determine the RP2D for FT819
Secondary: To evaluate the safety and tolerability of FT819 To evaluate the anti-tumor activity of FT819 To characterize the PK of FT819
Exploratory: For subjects with BCL, to evaluate the anti-tumor activity of FT819
To assess the association of PK and pharmacodynamics of FT819 with safety and anti-tumor activity To assess the association of clinical and tumor characteristics
with safety and anti-tumor activity of FT819 For subjects with B-ALL, to evaluate MRD status following treatment with FT819